New US approval for Clovis' Rubraca

9th April 2018 Uncategorised 0

Clovis’ PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.

More: New US approval for Clovis' Rubraca
Source: News